<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pediatr Nephrol</journal-id>
      <journal-title>Pediatric Nephrology (Berlin, Germany)</journal-title>
      <issn pub-type="ppub">0931-041X</issn>
      <issn pub-type="epub">1432-198X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17647026</article-id>
      <article-id pub-id-type="pmc">2064942</article-id>
      <article-id pub-id-type="publisher-id">524</article-id>
      <article-id pub-id-type="doi">10.1007/s00467-007-0524-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Educational Feature</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mechanisms of progression of chronic kidney disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Fogo</surname>
            <given-names>Agnes B.</given-names>
          </name>
          <address>
            <phone>+1-615-3223114</phone>
            <fax>+1-615-3437023</fax>
            <email>agnes.fogo@vanderbilt.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Department of Pathology, Vanderbilt University Medical Center, MCN C3310, Nashville, TN 37232 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>7</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2007</year>
      </pub-date>
      <volume>22</volume>
      <issue>12</issue>
      <fpage>2011</fpage>
      <lpage>2022</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>2</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>5</day>
          <month>4</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>4</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; IPNA 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Chronic kidney disease (CKD) occurs in all age groups, including children. Regardless of the underlying cause, CKD is characterized by progressive scarring that ultimately affects all structures of the kidney. The relentless progression of CKD is postulated to result from a self-perpetuating vicious cycle of fibrosis activated after initial injury. We will review possible mechanisms of progressive renal damage, including systemic and glomerular hypertension, various cytokines and growth factors, with special emphasis on the renin&#x2013;angiotensin&#x2013;aldosterone system (RAAS), podocyte loss, dyslipidemia and proteinuria. We will also discuss possible specific mechanisms of tubulointerstitial fibrosis that are not dependent on glomerulosclerosis, and possible underlying predispositions for CKD, such as genetic factors and low nephron number.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Angiotensin</kwd>
        <kwd>Angiotensin I converting enzyme inhibitors (ACEI)</kwd>
        <kwd>Angiotensin receptors</kwd>
        <kwd>Angiotensin receptor blockers</kwd>
        <kwd>Transforming growth factor (TGF)-beta</kwd>
        <kwd>Glomerulosclerosis</kwd>
        <kwd>Interstitial fibrosis</kwd>
        <kwd>Podocytes</kwd>
        <kwd>Low birth weight</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; IPNA 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Chronic kidney disease (CKD) occurs in all age groups, with an incidence in children between 1.5 per million and 3.0 per million. Renal developmental abnormalities (congenital abnormalities of the kidney and urinary tract, CAKUT) are the most common causes of CKD in children. Other diseases commonly underlying CKD in children include focal segmental glomerulosclerosis (FSGS), hemolytic uremic syndrome (HUS), immune complex diseases, and hereditary nephropathies, such as Alport&#x2019;s disease [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence of diabetes, especially type&#xA0;2, is increasing in children. Although CKD secondary to diabetes usually does not develop until adulthood, early structural lesions of diabetic nephropathy start in childhood [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>CKD shares a common appearance of glomerulosclerosis, vascular sclerosis and tubulointerstitial fibrosis, suggesting a common final pathway of progressive injury [<xref ref-type="bibr" rid="CR3">3</xref>]. Adaptive changes in nephrons after initial injury are postulated ultimately to be maladaptive, eventually causing scarring and further nephron loss, thus perpetuating a vicious cycle that results in the end-stage kidney. We will review possible mechanisms of progressive renal damage, which include, but are not limited to, hemodynamic factors, the renin&#x2013;angiotensin&#x2013;aldosterone system (RAAS), various cytokines and growth factors, podocyte loss, dyslipidemia, proteinuria, specific mechanisms of tubulointerstitial fibrosis, and possible underlying predispositions for CKD, such as genetic factors and low nephron number.</p>
      <sec id="Sec2">
        <title>Systemic and glomerular hypertension</title>
        <p>Systemic hypertension often accompanies renal disease and may both result from, and contribute to, CKD. Progression of CKD is accelerated by hypertension, and control of blood pressure is key in the treatment of CKD. In addition, the glomerulus has a unique structure, with both an afferent and an efferent arteriole, which permits modulation of glomerular perfusion and pressure without corresponding systemic blood pressure change.</p>
        <p>The remnant kidney model has been extensively studied to investigate CKD [<xref ref-type="bibr" rid="CR4">4</xref>]. In this model, one kidney and infarction/removal of two-thirds of the remaining kidney (i.e. five-sixths nephrectomy) results in progressive hyperperfusion, hyperfiltration, hypertrophy and FSGS [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. Additional models with initial podocyte injury, namely the puromycin aminonucleoside and adriamycin models of renal disease, show initial proteinuria and podocyte damage similar to human minimal-change disease, followed by progressive FSGS [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
        <p>Direct micropuncture studies have demonstrated that single nephron function was increased after renal ablation, and led to the hypothesis that hyperfiltration caused sclerosis, setting in motion a vicious cycle of hyperfiltration and glomerulosclerosis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Maneuvers that decreased hyperfiltration, such as low-protein diet, angiotensin&#xA0;I converting enzyme inhibitors (ACEIs), lipid-lowering agents, or heparin, were, indeed, effective in ameliorating glomerular sclerosis. However, in some studies, glomerular sclerosis was decreased without altering glomerular hyperfiltration [<xref ref-type="bibr" rid="CR9">9</xref>], and glomerular sclerosis occurred in some settings even in the absence of intervening hyperperfusion [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
        <p>Thus, focus was shifted to glomerular hypertension as a key mediator of progressive sclerosis. Maneuvers that increase glomerular capillary pressure, such as therapy with erythropoietin, glucocorticoids, or high-protein diet, accelerated glomerulosclerosis, while decreasing glomerular pressure ameliorated sclerosis. These beneficial effects were particularly apparent in the comparison of agents such as ACEIs that preferentially decrease glomerular pressure even more than systemic BP to non-specific antihypertensive agents [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      </sec>
      <sec id="Sec3">
        <title>Renin&#x2013;angiotensin&#x2013;aldosterone system</title>
        <p>The RAAS has been the focus of investigation of progression in CKD because of the efficacy of inhibition of its components in CKD. ACEIs decrease glomerular capillary pressure by preferential dilation of the efferent arteriole [<xref ref-type="bibr" rid="CR1">1</xref>], likely mediated by both inhibition of angiotensin&#xA0;II (AngII) and especially by the effect of ACEIs in augmenting bradykinin, which is degraded by angiotensin I converting enzyme (ACE) [<xref ref-type="bibr" rid="CR12">12</xref>]. Indeed, angiotensin type 1 receptor blockers (ARBs), which do not have this activity to increase bradykinin, do not preferentially dilate the efferent arteriole or decrease glomerular pressures to the extent of that seen with ACEIs in most experimental studies. However, both ACEIs and ARBs have shown superior efficacy in slowing progressive CKD in experimental models and in human CKD [<xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref>].</p>
        <p>ARBs leave the angiotensin type 2 (AT2) receptor active, and may in theory even lead to augmented AT2 effects by allowing unbound AngII to bind to this receptor. The AT2 receptor counteracts some of the classic AT1 receptor actions and thus is mildly vasodilating and mediates growth inhibition and apoptosis [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR20">20</xref>]. Apoptosis often is associated with decreased injury, as injured cells are quickly removed without activation of profibrotic cytokines and chemokines. Absence of AT2 receptor actions, either by pharmacological inhibition or by genetic absence, indeed resulted in diminished apoptosis after injury, associated with increased fibrosis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p>
        <p>Combined ACEI and AT1 receptor antagonist treatment could have a theoretic advantage, allowing further blockade of AngII actions while maintaining preferential local availability of the AT2 receptor [<xref ref-type="bibr" rid="CR23">23</xref>]. In an experimental model, combined ACEI and ARB therapy did not result in added benefit on glomerulosclerosis when compared with single-drug therapy with similar blood pressure control [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. However, addition of AT2 receptor inhibition to ARB treatment prevented the beneficial effects of ARBs  [<xref ref-type="bibr" rid="CR26">26</xref>]. A beneficial effect of the AT2 receptor in renal injury was also demonstrated in transgenic mice overexpressing the AT2 receptor. These mice developed less severe injury than did the wild type after subtotal nephrectomy [<xref ref-type="bibr" rid="CR27">27</xref>]. Results from small clinical studies of human CKD suggest that the combination of ARBs and ACEIs has greater effect in the decrease of proteinuria, not attributable to effects on systemic blood pressure [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In a large study of hypertensive patients with diabetic nephropathy and microalbuminuria, combined therapy resulted in greater reduction of  blood pressure and albuminuria than did therapy with either drug alone [<xref ref-type="bibr" rid="CR30">30</xref>]. In a Japanese study, in addition to decreased proteinuria, the slope of decline of glomerular filtration rate (GFR) improved with combination ACEI and ARB versus monotherapy [<xref ref-type="bibr" rid="CR31">31</xref>]. However, complete dose-range comparisons of combined therapy with monotherapy were not made in these clinical trials. A recent review of clinical trials with combination therapy with ACEI and ARB in CKD patients support that such combination therapy had increased effects to decrease proteinuria without significantly increasing adverse side effects [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
        <p>Antifibrotic effects of combination therapy versus monotherapy could include augmented bradykinin and AT2 activity and also decreased urinary transforming growth factor (TGF)-&#x3B2; [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, there may be greater suppression of the renin&#x2013;angiotensin system (RAS) with combined therapy, decreasing both ligand generation by inhibition of ACE and binding of any remaining AngII to the AT1 receptor. However, even suprapharmacological doses of ACE inhibition did not achieve complete suppression of the local RAS in experimental models [<xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, patients receiving ACEIs long term still have measurable ACE in their plasma. These data support the notion that non-ACE-dependent AngII generation by chymotrypsin-sensitive generating enzyme occurs in humans. New directions under investigation include the development of renin antagonists that could obviate these obstacles to optimal inhibition of the RAAS. Renin itself may have direct effects, independent of activation of the RAAS, with renin receptor activity detected on mesangial cells [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p>Many profibrotic actions of the RAAS are mediated directly by AngII. AngII promotes migration of endothelial and vascular smooth muscle cells, and hypertrophy and hyperplasia of smooth muscle cells and mesangial cells [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. All components of the RAS are present in macrophages, which may thus serve as yet another source of AngII and also respond to ACEI and ARB. AngII also induces other growth factors, including basic fibroblast growth factor (basic FGF), platelet-derived growth factor (PDGF) and TGF-&#x3B2;, and plasminogen activator inhibitor-1 (PAI-1), all of which may impact on fibrosis (see below), [<xref ref-type="bibr" rid="CR37">37</xref>&#x2013;<xref ref-type="bibr" rid="CR39">39</xref>].</p>
        <p>Importantly, new data indicate that aldosterone has both genomic and non-genomic actions to promote fibrosis, independent of its actions to increase blood pressure by mediating salt retention [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Aldosterone enhances angiotensin induction of PAI-1 (see below), and also has direct actions on fibrosis [<xref ref-type="bibr" rid="CR40">40</xref>]. Conversely, aldosterone receptor antagonism with spironolactone decreased injury [<xref ref-type="bibr" rid="CR40">40</xref>]. PAI-1 deficiency prevented aldosterone-induced glomerular injury, but interestingly did not alter cardiac or aortic injury in this mouse model, suggesting site-specific and perhaps species-specific mechanisms of aldosterone-PAI-1 mediated fibrosis [<xref ref-type="bibr" rid="CR42">42</xref>]. In clinical trials, aldosterone antagonism has further decreased proteinuria when added to ACEI and ARB therapy [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. However, the potential risk of hyperkalemia may limit the ability to add aldosterone antagonism to angiotensin inhibition. Whether these approaches also apply to children with CKD has not been investigated.</p>
        <p>Clearly, the RAAS has many non-hemodynamic actions and thus, doses beyond usual antihypertensive doses are potentially of additional benefit. Regression has even been achieved in experimental models with high-dose ACEI/ARB. A shift in the balance of synthesis/degradation of extracellular matrix (ECM) must occur to accomplish regression of sclerosis; endothelial cells must regenerate, mesangial cells must regrow, and finally, podocytes must be restored. New glomeruli cannot be generated after term birth in humans. However, remaining segments of non-sclerotic loops can give rise to more open capillary area by lengthening or branching of the remaining capillaries [<xref ref-type="bibr" rid="CR45">45</xref>&#x2013;<xref ref-type="bibr" rid="CR48">48</xref>]. Recent experimental data show that regression can, indeed, be induced by high-dose ACEI or ARB or spironolactone, linked to decreased PAI-1, restored plasmin activity and capillary remodeling [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x2013;<xref ref-type="bibr" rid="CR51">51</xref>]. Of note, regression was not associated with increased expression or activity of matrix metalloproteases-2 or -9 or decreased mRNA for TGF-&#x3B2; or local decreases in TGF-&#x3B2; expression as assessed by in situ hybridization. However, lack of changes in mRNA does not rule out that local changes in TGF-&#x3B2; actions could occur, and clearly, in many systems, TGF-&#x3B2; has been shown to impact on ECM accumulation. Regression is also possible in human CKD, demonstrated in principle by regression of early diabetic sclerosis and tubulointerstitial fibrosis in patients over a 10-year period when the underlying diabetes was cured by pancreas transplantation [<xref ref-type="bibr" rid="CR52">52</xref>]. Regression of existing lesions also occurred in IgA nephropathy in response to high-dose corticosteroids and tonsillectomy [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Specific cytokines/growth factors and progression of CKD</title>
        <p>Numerous cytokines/growth factors appear to modulate progression of glomerular and tubulointerstitial scarring. These factors and their roles may differ at the various stages of injury. Altered gene expressions and/or pharmacologic manipulations in pathophysiological settings have implicated e.g. PDGF, TGF-&#x3B2;, AngII, basic FGF, endothelin, various chemokines, peroxisome proliferator-activated receptor-&#x3B3; (PPAR-&#x3B3;) and PAI-1, among others, in progressive renal scarring [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#x2013;<xref ref-type="bibr" rid="CR56">56</xref>]. Current state-of-the-art approaches with proteomic and array analysis of renal tissue in human CKD and in animal models can identify novel targets and markers, and even mediators of progression [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Of these many potential molecules of interest, we will discuss only a few that have been investigated in depth.</p>
        <p>Increased PAI-1 is associated with increased cardiovascular disease and fibrotic kidney disease [<xref ref-type="bibr" rid="CR59">59</xref>]. Conversely, PAI-1 could be decreased by inhibition of AngII and/or aldosterone, and linked to prevention of sclerosis or even regression of existing kidney fibrosis [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. AngII and aldosterone can also induce PAI-1 expression and subsequent fibrosis independent of TGF-&#x3B2; activation [<xref ref-type="bibr" rid="CR61">61</xref>]. Some of the effects of PAI-1 in promoting fibrosis are independent of its effects on proteolysis. PAI-1 also modulates cell migration, perhaps by its effects on vitronectin interaction [<xref ref-type="bibr" rid="CR59">59</xref>]. Thus, PAI-1 may in some inflammatory or interstitial disease settings increase fibrosis primarily by enhancing cell migration and epithelial-mesenchymal transition (EMT). In contrast, in the glomerulus, the effects of PAI-1 in the increase of sclerosis may predominantly be due to its ability to modulate ECM turnover [<xref ref-type="bibr" rid="CR59">59</xref>]. These data support that mechanisms of fibrosis in the interstitium and glomerulus are not identical, and involve complex interactions of parenchymal and infiltrating cells and cytokines, with variable net effects on ECM accumulation.</p>
        <p>TGF-&#x3B2; promotes ECM synthesis and is a key promoter of fibrosis. The biological actions of TGF-&#x3B2; are complex and depend not only on cell state, but also on the presence of decorin and latency-associated peptide (LAP), both of which can bind and modify its activity [<xref ref-type="bibr" rid="CR37">37</xref>]. TGF-&#x3B2; also induces both PAI-1 and AngII [<xref ref-type="bibr" rid="CR62">62</xref>]. Animals transgenic for TGF-&#x3B2; developed progressive renal disease [<xref ref-type="bibr" rid="CR63">63</xref>]. Conversely, inhibition of either TGF-&#x3B2; or PDGF-B decreased mesangial matrix expansion in the anti-Thy1 model [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Animals genetically deficient for TGF-&#x3B2; develop lymphoproliferative disease, thought to reflect a loss of TGF-&#x3B2; immune regulatory effect [<xref ref-type="bibr" rid="CR66">66</xref>]. Interestingly, pharmacologic inhibition of TGF-&#x3B2; was more effective at lower dose, and with higher dose of anti-TGF-&#x3B2; associated with more fibrosis and greater macrophage influx, perhaps also reflecting effects on TGF-&#x3B2; immune modulation [<xref ref-type="bibr" rid="CR67">67</xref>]. TGF-&#x3B2; may promote a more fibroblastic phenotype of the podocyte, with loss of differentiation markers and de novo expression of alpha-smooth muscle actin [<xref ref-type="bibr" rid="CR68">68</xref>]. Although TGF-&#x3B2; promotes growth arrest and differentiation of podocytes at low doses, at higher doses, TGF-&#x3B2; causes podocyte apoptosis, mediated by Smad&#xA0;7 signaling [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Loss of podocytes (see below) is a key factor contributing to progressive kidney fibrosis.</p>
        <p>PPAR-&#x3B3; modifies numerous cytokines and growth factors, including PAI-1 and TGF-&#x3B2;. PPAR-&#x3B3; is a transcription factor and a member of the steroid superfamily [<xref ref-type="bibr" rid="CR71">71</xref>]. On activation, PPAR-&#x3B3; binds the retinoic acid X receptor, translocates to the nucleus and binds to peroxisome proliferator activator response elements (PPREs) in selected target genes, modifying their expression. PPAR-&#x3B3; agonists, such as the thiazolidinediones, are most commonly used to treat type 2 diabetes, due to their beneficial effects to increase insulin sensitivity and improve lipid metabolism, and they have been shown to decrease diabetic injury correspondingly in diabetic animal models [<xref ref-type="bibr" rid="CR72">72</xref>]. Interestingly, PPAR-&#x3B3; agonists also have antifibrotic effects in non-diabetic or non-hyperlipidemic experimental models of CKD. PPAR-&#x3B3; agonist ameliorated the development of sclerosis in these non-diabetic models, linked to decreased PAI-1 and TGF-&#x3B2; and decreased infiltrating macrophages and protection of podocytes against injury [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Further study is necessary to determine the specific role each of the above factors plays at varying stages of renal fibrosis.</p>
      </sec>
      <sec id="Sec5">
        <title>Podocyte loss</title>
        <p>Podocytes are the primary target in many glomerular diseases, including FSGS and the experimental models of adriamycin and puromycin aminonucleoside-induced nephropathies [<xref ref-type="bibr" rid="CR74">74</xref>]. The podocytes are pivotal for maintenance of normal permselectivity, and are a source of matrix in both physiological and pathophysiological settings. The podocyte does not normally proliferate. Loss of podocytes after injury is postulated to be a key factor resulting in progressive sclerosis [<xref ref-type="bibr" rid="CR74">74</xref>]. This principle was proven in experimental models in mice and rats, where podocyte-specific injury was produced by genetic manipulation of the podocytes to express toxin receptors only on this cell [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. Injection of toxin then resulted in podocyte loss, the degree of which depended on toxin dose. Animals subsequently developed progressive sclerosis. Of interest, even though only podocytes were initially injured, subsequent injury rapidly also developed in endothelial and mesangial cells, with resulting sclerosis. Even when chimeric mice were genetically engineered so that only a portion of their podocytes was susceptible to the toxin, all podocytes developed injury after toxin exposure [<xref ref-type="bibr" rid="CR77">77</xref>]. These data show that injury can also spread from the initially injured podocyte to initially intact podocytes within a glomerulus, setting up a vicious cycle of progressive injury at the glomerular level [<xref ref-type="bibr" rid="CR77">77</xref>].</p>
        <p>The limited proliferation in the mature podocyte is accompanied by high expression of a cyclin-dependent kinase inhibitor, p27kip1, a rate-limiting step for the growth response of the podocyte [<xref ref-type="bibr" rid="CR78">78</xref>]. Either too much or too little proliferation of the podocyte in response to genetic manipulation of p27kip1 is postulated be detrimental [<xref ref-type="bibr" rid="CR79">79</xref>]. Inadequate growth of the podocyte is postulated to give rise to areas of dehiscence and insudation of plasma proteins, which progress to adhesions and sclerosis [<xref ref-type="bibr" rid="CR80">80</xref>]. Another cyclin-dependent kinase inhibitor, p21, appears to be necessary for development of injury after five-sixths nephrectomy in mice, pointing to the crucial importance of cell growth responses in determining response to injury [<xref ref-type="bibr" rid="CR81">81</xref>].</p>
        <p>Podocytes normally produce an endogenous heparin-like substance, which inhibits mesangial cell growth; thus, injury may decrease this growth inhibitory effect and allow increased mesangial growth. Podocytes are also the main renal source of angiopoietin-1 and vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen that plays a key role in both physiologic and pathologic angiogenesis and vascular permeability [<xref ref-type="bibr" rid="CR82">82</xref>]. Overexpression or partial loss of podocyte VEGF results in a collapsing lesion or pre-eclampsia-like endotheliosis lesion, respectively [<xref ref-type="bibr" rid="CR82">82</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Podocyte genes and CKD</title>
        <p>New studies of the molecular biology of the podocyte and identification of genes mutated in rare familial forms of FSGS and nephrotic syndrome, such as nephrin, WT-1, transient receptor potential cation channel-6 (TRPC-6), phospholipase C epsilon, &#x3B1;-actinin-4 and podocin, have given important new insights into mechanisms of progressive glomerulosclerosis. The gene mutated for congenital nephrotic syndrome, nephrin (NPHS1) is localized to the slit diaphragm of the podocyte and is tightly associated with CD2-associated protein (CD2AP) [<xref ref-type="bibr" rid="CR83">83</xref>]. Nephrin functions as a zona occludens-type junction protein, and together with CD2AP, provides a crucial role in receptor patterning and cytoskeletal polarity and also provides signaling function of the slit diaphragm [<xref ref-type="bibr" rid="CR84">84</xref>]. Mice with CD2AP knockout develop congenital nephrotic syndrome, similar to congenital nephrotic syndrome of Finnish type [<xref ref-type="bibr" rid="CR85">85</xref>]. Autosomal dominant FSGS with adult onset is caused by mutation in &#x3B1;-actinin 4 (ACTN4) [<xref ref-type="bibr" rid="CR86">86</xref>]. This is hypothesized to cause altered actin&#x2013;cytoskeleton interaction, causing FSGS through a gain-of-function mechanism, in contrast to the loss-of-function mechanism implicated for disease caused by the nephrin mutation [<xref ref-type="bibr" rid="CR85">85</xref>]. Patients with &#x3B1;-actinin 4 mutation progress to end-stage by age 30&#xA0;years, with rare recurrence in a transplant. TRPC-6 encodes for a cation channel, which is present in several sites including podocytes. TRPC-6 is mutated in some kindreds with familial FSGS with adult onset in an autosomal dominant pattern [<xref ref-type="bibr" rid="CR87">87</xref>]. Podocin, another podocyte-specific gene (NPHS2), is mutated in autosomal recessive FSGS with childhood onset with rapid progression to end-stage kidney disease [<xref ref-type="bibr" rid="CR88">88</xref>]. Podocin interacts with the CD2AP-nephrin complex, indicating that podocin could serve in the structural organization of the slit diaphragm. In some series of steroid-resistant pediatric patients with non-familial forms of FSGS, a surprisingly high proportion, up to 25%, had podocin mutations [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. However, not all patients with nephrotic syndrome caused by mutation are steroid resistant. Diffuse mesangial sclerosis in a large kindred was recently linked to a truncating mutation of phospholipase C epsilon (PLCE1), and two of those patients responded to steroid therapy [<xref ref-type="bibr" rid="CR91">91</xref>]. However, in two patients with missense mutation of this same gene, FSGS lesions developed, demonstrating that a spectrum of structural abnormalities may arise from varying mutations in the same gene. PLCE1 is expressed in the glomerulus, where it is postulated to play a key role in development, perhaps by interacting with other proteins that are crucial for the development and function of the slit diaphragm.</p>
        <p>WT-1 mutation, which may occur sporadically with only FSGS or be associated with Denys&#x2013;Drash syndrome, was found in only 5% of steroid-resistant patients [<xref ref-type="bibr" rid="CR92">92</xref>]. Interestingly, mutations of podocin or WT-1 were not found in relapsing or steroid-dependent pediatric patients [<xref ref-type="bibr" rid="CR93">93</xref>]. Acquired disruption or polymorphisms of some of these complexly interacting molecules have been demonstrated in experimental models and in human proteinuric diseases. Thus, in puromycin aminonucleoside nephropathy, a model of FSGS, nephrin localization and organization were altered [<xref ref-type="bibr" rid="CR94">94</xref>]. Similar decreases in nephrin were observed in hypertensive diabetic rat models with significant proteinuria [<xref ref-type="bibr" rid="CR95">95</xref>]. TRPC-6, a calcium channel, was induced in various non-genetic human proteinuric diseases [<xref ref-type="bibr" rid="CR96">96</xref>]. Conversely, treatments that ameliorated these experimental models preserved e.g. glomerular nephrin expression, providing further support for a key causal role for slit diaphragm and key podocyte molecules in proteinuria [<xref ref-type="bibr" rid="CR97">97</xref>]. Whether polymorphisms, compound heterozygosity for mutations or merely altered distribution and/or expression of any of these proteins contribute to proteinuria or progressive disease in various causes of CKD in humans has not been determined.</p>
      </sec>
      <sec id="Sec7">
        <title>Dyslipidemia</title>
        <p>Patients with CKD frequently have dyslipidemia and greatly increased cardiovascular disease risk, even beyond that predicted by lipid abnormalities [<xref ref-type="bibr" rid="CR98">98</xref>]. Abnormal lipids are important in modulating glomerular sclerosis in rats; however, analogous studies in humans are still evolving [<xref ref-type="bibr" rid="CR99">99</xref>&#x2013;<xref ref-type="bibr" rid="CR102">102</xref>]. Glomerular injury was increased in experimental CKD when excess cholesterol was added to the diets. Glomerular disease has been reported in the rare familial disease, lecithin cholesterol acyltransferase deficiency, and with excess apolipoprotein&#xA0;E. However, renal disease is not typical in the more common forms of primary hyperlipidemias. Patients with minimal-change disease or membranous glomerulonephritis, characterized by hyperlipidemia as part of their nephrotic syndrome, usually do not develop glomerular scarring. However, recently, post hoc and meta-analyses of clinical trial data support that abnormal lipids are associated with increased loss of GFR and that treatment with statins may not only benefit cardiovascular disease risk, but also be of benefit for progressive CKD. A post hoc analysis suggests that statins may even slow progression in patients with stage 3&#xA0;CKD [<xref ref-type="bibr" rid="CR102">102</xref>]. These beneficial effects of statins appear to extend beyond their lipid-lowering effects [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR101">101</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Proteinuria</title>
        <p>Proteinuria is a marker of renal injury, reflecting loss of normal permselecitvity. Further, proteinuria itself has been proposed to contribute to progressive renal injury inflammation [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Increased proteinuria is associated with worse prognosis [<xref ref-type="bibr" rid="CR104">104</xref>]. Whether proteinuria is merely a marker of injury or a contributor to progressive injury has been debated.</p>
        <p>Albumin can in vitro in tubular cells increase AngII and in turn upregulate TGF-&#x3B2; receptor expression [<xref ref-type="bibr" rid="CR105">105</xref>]. However, in most settings, pure albumin per se is not directly injurious. Other filtered components of the urine in proteinuric states, such as oxidized proteins, appear to be more potent in inducing direct injury of tubular epithelial cells and activating proinflammatory and fibrotic chemokines and cytokines. Complement and various lipoproteins are also present in the urine in proteinuric disease states and can activate reactive oxygen species [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. Proteinuria may thus alter tubule cell function directly, potentially contributing to a more profibrotic phenotype, and also augment interstitial inflammation, in particular by macrophages. Proteinuria may activate many profibrotic pathways through its ability to increase NF-kB, and also by other pathways. These include for instance complement synthesis from tubules [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
        <p>Interventions that are particularly effective in decreasing proteinuria, such as the administration of ACEIs or ARBs, also decrease overall end organ injury. Whether these beneficial effects are dependent on the reduction of proteinuria has not been proven, in that these interventions have multiple parallel effects that may all contribute to the decrease of fibrosis [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Mechanisms of tubulointerstitial fibrosis</title>
        <p>Tubulointerstitial fibrosis classically was thought merely to reflect glomerular injury and resulting whole nephron ischemia in most CKD. Interesting new data point to independent mechanisms of interstitial fibrosis and the importance of the tubulointerstitial lesion in progression. Decreased peritubular capillary density, possibly modulated by decreased VEGF or other angiogenic factors, has been proposed as a mechanism in various progressive renal diseases [<xref ref-type="bibr" rid="CR108">108</xref>]. Future studies may demonstrate whether these interstitial microvascular lesions are causal or consequential in the development of interstitial injury.</p>
        <p>Increased numbers of macrophages are closely correlated with both glomerulosclerosis and tubulointerstitial fibrosis and are usually decreased by interventions that decrease fibrosis. These cells are potential sources of numerous cytokines and eicosanoids that affect the glomerulus [<xref ref-type="bibr" rid="CR109">109</xref>]. Support for this hypothesis is seen with the protective effects of maneuvers that decrease macrophage influx. In a rat model of unilateral ureteral obstruction (UUO), administration of ACEI ameliorated interstitial monocyte/macrophage infiltration and decreased fibrosis [<xref ref-type="bibr" rid="CR110">110</xref>]. Studies in &#x3B2;6&#xA0;integrin-deficient mice revealed that infiltrating macrophages do not inevitably transduce fibrotic effects; in these mice local activation of TGF-&#x3B2; is impaired, and they are protected from fibrosis despite abundant macrophage infiltration [<xref ref-type="bibr" rid="CR61">61</xref>]. Macrophages may even play a beneficial role in scarring. The specific role of the macrophage AT1a receptor in renal fibrosis was examined in studies of bone marrow transplantation in wild type mice with UUO mice reconstituted with either wild type macrophages or macrophages devoid of the AT1a receptor. There was more severe interstitial fibrosis in mice with the AT1a deficient macrophages, even though fewer infiltrating macrophages were observed, suggesting that the macrophage AT1a receptor functions to protect the kidney from fibrogenesis [<xref ref-type="bibr" rid="CR111">111</xref>].</p>
        <p>In human diabetic nephropathy there is an early increase in total interstitial cell volume (which may represent increased cell size and/or number), preceding the accumulation of interstitial collagen [<xref ref-type="bibr" rid="CR112">112</xref>]. This is in contrast to the diabetic glomerular lesion, where the expanded mesangial area is largely due to increased matrix accumulation rather than hypercellularity. These interstitial cells could possibly represent interstitial myofibroblasts, postulated to play a key role in interstitial fibrosis. These activated interstitial cells are a major source of collagen synthesis, and increased expression of &#x3B1;-smooth muscle actin (SMA), a marker of myofibroblasts, predicts progressive renal dysfunction both in human and experimental renal disease.</p>
        <p>The source of interstitial myofibroblasts is a topic of controversy. Bone marrow-derived or potential renal stem cells may give rise not only to interstitial cells but also to regenerating parenchymal cells [<xref ref-type="bibr" rid="CR113">113</xref>]. Epithelial&#x2013;mesenchymal transformation (EMT) is another possible mechanism for generation of interstitial myofibroblasts [<xref ref-type="bibr" rid="CR114">114</xref>]. This seamless plasticity of cells changing from epithelial to mesenchymal phenotypes exists during early development. EMT may also occur in the adult after injury, contributing approximately half of the interstitial fibroblasts in experimental models [<xref ref-type="bibr" rid="CR114">114</xref>]. Injured tubular epithelial cells can change phenotype both in vivo and in vitro, with de novo expression of a fibroblast-specific protein (FSP1), and possibly migrate into the interstitium as myofibroblasts. The surrounding matrix and basement membrane underlying the tubular epithelium is disrupted by local proteolysis, modulated by an array of cytokines and growth factors, including insulin-like growth factors&#xA0;I and II, integrin-linked kinases, EGF, FGF-2 and TGF-&#x3B2; [<xref ref-type="bibr" rid="CR114">114</xref>]. Several key factors inhibit EMT, including hepatocyte growth factor and bone morphogenetic factor-7, and thus inhibit fibrosis in experimental CKD [<xref ref-type="bibr" rid="CR114">114</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Anatomic and genetic risks for CKD: nephron number and gene polymorphisms</title>
        <p>Risk for development of CKD and its rate of progression varies in differing populations. CKD associated with hypertension and arterio-nephrosclerosis is particularly common in African Americans, and FSGS is more frequently the underlying cause of steroid-resistant FSGS in African Americans and Hispanics than in Caucasians [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. These varying disease trends in differing ethnic populations could represent both genetic and environmental factors. Low birth weight is epidemiologically linked to increased risk for cardiovascular disease, hypertension and CKD in adulthood. The link is postulated to be due to the decreased nephron number that accompanies low term birth weight, defined as less than 2,500&#xA0;g [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. These fewer nephrons are postulated to be under greater hemodynamic stress, thus contributing to progressive sclerosis. Of interest, low birth weight is much more common in African Americans than in Caucasians and is not accounted for by socioeconomic status [<xref ref-type="bibr" rid="CR119">119</xref>]. Further, glomerular size in normal African Americans is larger than in Caucasians and could possibly reflect smaller nephron number [<xref ref-type="bibr" rid="CR120">120</xref>]. In Australian Aborigines, marked increase in incidence of CKD is associated with larger but fewer glomeruli and low birth weight [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. Mechanisms other than hemodynamic stress that could underlie these differences in normal glomerular populations and also relate to increased incidence of end-stage renal disease include functional polymorphisms of genes that are involved both in renal/glomerular development and contribute to amplified scarring mechanisms, such as the renin&#x2013;angiotensin system [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
        <p>African Americans also have increased severity of renal disease associated with several systemic conditions. The course of lupus nephritis in a prospective trial was more severe in African Americans than in Caucasians, with more extensive crescent formation and interstitial fibrosis and greater likelihood of end-stage renal disease [<xref ref-type="bibr" rid="CR123">123</xref>]. Even the manifestations of HIV infection in the kidney differ markedly between African Americans and Caucasians: HIV-associated renal disease in African Americans is typically an aggressive collapsing type of FSGS, contrasting lower grade immune-complex-mediated glomerulonephritides in Caucasians with HIV infection and renal disease [<xref ref-type="bibr" rid="CR124">124</xref>]. Genetic background also modulates susceptibility in experimental models, both to podocyte injury (e.g. only the balb/c mouse strain is susceptible to adriamycin) and to hypertension injury (e.g. in the five-sixths nephrectomy model, C57Bl mice are resistant, 129Sv/J mice are susceptible) and even to diabetic injury [<xref ref-type="bibr" rid="CR125">125</xref>&#x2013;<xref ref-type="bibr" rid="CR127">127</xref>].</p>
        <p>There is also accumulating evidence that specific genes in humans modulate the course and rate of organ damage. Polymorphisms in several genes within the RAAS system, including ACE, angiotensinogen and the angiotensin type&#xA0;1 receptor, have been linked with cardiovascular and renal disorders, including diabetic nephropathy, IgA nephropathy and uropathies [<xref ref-type="bibr" rid="CR128">128</xref>&#x2013;<xref ref-type="bibr" rid="CR133">133</xref>]. The ACE DD genotype, associated with increased RAS activity, was increased in patients with IgA nephropathy who ultimately experienced progressive decline in renal function during follow-up compared with those whose function remained stable over the same time [<xref ref-type="bibr" rid="CR134">134</xref>].</p>
        <p>Polymorphisms of TGF-&#x3B2; are also implicated in hypertension and progressive fibrosis. The Arg 25 polymorphism may be increased in African Americans, who may also have greater elevation of circulating TGF-&#x3B2; when they reach end-stage renal disease than do Caucasians [<xref ref-type="bibr" rid="CR135">135</xref>].</p>
        <p>These observations suggest that complex genetic traits can modulate the response of glomerular cells to pathogenic stimuli in experimental models. Whether ethnic differences in development of renal disease in humans reflect contributions of genetic and/or environmental influences remains to be definitively determined.</p>
        <p>QUESTIONS (Answers appear following the reference list)
<list list-type="order"><list-item><p>A 6-year-old African American boy presented with generalized edema, 24&#xA0;h urine protein excretion of 1.5&#xA0;g and normal complements, and serum creatinine of 0.7&#xA0;mg/dl. His blood pressure was 110/70&#xA0;mmHg. His nephrotic syndrome did not respond to an 8-week course of steroids, and a renal biopsy is planned. The most likely diagnosis in this patient is:
<list list-type="order"><list-item><p>FSGS due to mutation of podocin</p></list-item><list-item><p>Minimal-change disease</p></list-item><list-item><p>FSGS, usual type</p></list-item><list-item><p>Diffuse mesangial sclerosis</p></list-item><list-item><p>Collapsing glomerulopathy</p></list-item></list></p></list-item><list-item><p>For the same patient detailed in question 1, what additional treatment should be initiated at this time to decrease risk of CKD:
<list list-type="order"><list-item><p>Diuretics</p></list-item><list-item><p>Spironolactone</p></list-item><list-item><p>ACEIs</p></list-item><list-item><p>Beta blockers</p></list-item><list-item><p>ACEIs and ARBs</p></list-item></list></p></list-item><list-item><p>In the same patient detailed in the above questions, what parameters would be most important to follow and evaluate for adjustment of therapy:
<list list-type="order"><list-item><p>Edema</p></list-item><list-item><p>White blood cell (WBC) count</p></list-item><list-item><p>Blood pressure</p></list-item><list-item><p>Proteinuria</p></list-item></list></p></list-item><list-item><p>A 14-year-old Caucasian girl was diagnosed with IgA nephropathy, which on biopsy showed fibrocellular crescents, with focal proliferative and secondary sclerosing lesions of glomeruli. Her urine protein excretion was 1.0&#xA0;g in 24&#xA0;h. Urinalysis showed frequent red blood cell casts, serum creatinine was 1.2&#xA0;mg/dl and her blood pressure was 120/93&#xA0;mmHg. Which of the following mechanisms are likely to contribute to progression of her CKD:
<list list-type="order"><list-item><p>Podocyte loss</p></list-item><list-item><p>Proteinuria</p></list-item><list-item><p>Glomerular hypertension</p></list-item><list-item><p>Infiltrating macrophages</p></list-item><list-item><p>All of the above</p></list-item></list></p></list-item><list-item><p>A 10-year-old Caucasian boy with a history of multiple episodes of steroid-dependent nephrotic syndrome since the age of 4&#xA0;years now has proteinuria of 3.8&#xA0;g in 24&#xA0;h, with unremarkable urinalysis without red blood cell casts; his serum creatinine is 0.6&#xA0;mg/dl, and his blood pressure is 98/64&#xA0;mmHg. He has an increased cholesterol level of 480&#xA0;mg/dl and triglyceride levels are 110&#xA0;mg/dl. What mechanisms of renal injury are likely to be activated in this child:
<list list-type="order"><list-item><p>podocyte loss</p></list-item><list-item><p>proteinuria</p></list-item><list-item><p>dyslipidemia</p></list-item><list-item><p>glomerular hypertension</p></list-item><list-item><p>(b) and (c)</p></list-item></list></p></list-item></list></p>
      </sec>
    </sec>
  </body>
  <back>
    <!-- WARNING: ArticleNote has not been converted -->
    <ack>
      <title>Acknowledgment</title>
      <p>This work was supported in part by NIH grants DK 44757 and DK 56942.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foreman</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JCM</given-names>
            </name>
          </person-group>
          <article-title>Chronic renal failure in infants and children</article-title>
          <source>J Pediatr</source>
          <year>1988</year>
          <volume>113</volume>
          <fpage>793</fpage>
          <lpage>800</lpage>
        </citation>
        <citation citation-type="display-unstructured">Foreman JW, Chan JC (1988) Chronic renal failure in infants and children. J Pediatr 113:793&#x2013;800 <pub-id pub-id-type="pmid">3054033</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drummond</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>M</given-names>
            </name>
            <collab>International Diabetic Nephropathy Study Group</collab>
          </person-group>
          <article-title>The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes</article-title>
          <source>Diabetes</source>
          <year>2002</year>
          <volume>51</volume>
          <fpage>1580</fpage>
          <lpage>1587</lpage>
        </citation>
        <citation citation-type="display-unstructured">Drummond K, Mauer M, International Diabetic Nephropathy Study Group (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580&#x2013;1587 <pub-id pub-id-type="pmid">11978659</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Heptinstall</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Nonimmunologic mechanisms of glomerular injury</article-title>
          <source>Lab Invest</source>
          <year>1988</year>
          <volume>59</volume>
          <fpage>564</fpage>
          <lpage>578</lpage>
        </citation>
        <citation citation-type="display-unstructured">Olson JL, Heptinstall RH (1988) Nonimmunologic mechanisms of glomerular injury. Lab Invest 59:564&#x2013;578 <pub-id pub-id-type="pmid">3054312</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morrison</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>The functional capacity of hypertrophied nephrons: effect of partial nephrectomy on the clearance of inulin and PAH in the rat</article-title>
          <source>J Exp Med</source>
          <year>1966</year>
          <volume>123</volume>
          <fpage>829</fpage>
          <lpage>844</lpage>
        </citation>
        <citation citation-type="display-unstructured">Morrison AB, Howard RM (1966) The functional capacity of hypertrophied nephrons: effect of partial nephrectomy on the clearance of inulin and PAH in the rat. J Exp Med 123:829&#x2013;844 <pub-id pub-id-type="pmid">5938815</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats</article-title>
          <source>Am J Pathol</source>
          <year>1975</year>
          <volume>79</volume>
          <fpage>95</fpage>
          <lpage>106</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shimamura T, Morrison AB (1975). A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79:95&#x2013;106 <pub-id pub-id-type="pmid">164779</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hostetter</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rennke</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Venkatachalam</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation</article-title>
          <source>Am J Physiol</source>
          <year>1981</year>
          <volume>241</volume>
          <fpage>F85</fpage>
          <lpage>F93</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241:F85&#x2013;F93 <pub-id pub-id-type="pmid">7246778</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grond</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weening</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Elema</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside</article-title>
          <source>Lab Invest</source>
          <year>1984</year>
          <volume>51</volume>
          <fpage>277</fpage>
          <lpage>285</lpage>
        </citation>
        <citation citation-type="display-unstructured">Grond J, Weening JJ, Elema JD (1984) Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 51:277&#x2013;285 <pub-id pub-id-type="pmid">6471809</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenner</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Hostetter</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title>Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease</article-title>
          <source>N Engl J Med</source>
          <year>1982</year>
          <volume>307</volume>
          <fpage>652</fpage>
          <lpage>659</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652&#x2013;659 <pub-id pub-id-type="pmid">7050706</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nath</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Kren</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Hostetter</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title>Dietary protein restriction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction</article-title>
          <source>J Clin Invest</source>
          <year>1986</year>
          <volume>78</volume>
          <fpage>1199</fpage>
          <lpage>1205</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nath KA, Kren SM, Hostetter TH (1986) Dietary protein restriction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction. J Clin Invest 78:1199&#x2013;1205 <pub-id pub-id-type="pmid">3771792</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases</article-title>
          <source>Kidney Int Suppl</source>
          <year>2000</year>
          <volume>75</volume>
          <fpage>S15</fpage>
          <lpage>S21</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fogo AB (2000) Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 75:S15&#x2013;21 <pub-id pub-id-type="pmid">10828756</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kakinuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bills</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshioka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Blood-pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure</article-title>
          <source>Kidney Int</source>
          <year>1992</year>
          <volume>42</volume>
          <fpage>46</fpage>
          <lpage>55</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A (1992) Blood-pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46&#x2013;55 <pub-id pub-id-type="pmid">1635354</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition</article-title>
          <source>Kidney Int</source>
          <year>1993</year>
          <volume>44</volume>
          <fpage>545</fpage>
          <lpage>550</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kon V, Fogo A, Ichikawa I (1993) Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 44:545&#x2013;550 <pub-id pub-id-type="pmid">8231026</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Hunsicker</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Bain</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy</article-title>
          <source>N Engl J Med</source>
          <year>1993</year>
          <volume>330</volume>
          <fpage>1456</fpage>
          <lpage>1462</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 330:1456&#x2013;1462 <pub-id pub-id-type="pmid">8413456</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasiske</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Kalil</surname>
              <given-names>RSN</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>JZ</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keane</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>The effect of blood pressure treatment on the kidney in diabetes: a meta-regression analysis</article-title>
          <source>Ann Intern Med</source>
          <year>1993</year>
          <volume>118</volume>
          <fpage>129</fpage>
          <lpage>138</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF (1993) The effect of blood pressure treatment on the kidney in diabetes: a meta-regression analysis. Ann Intern Med 118:129&#x2013;138 <pub-id pub-id-type="pmid">8416309</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maschio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Alberti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Janin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Locatelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Motolese</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ponticelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zucchelli</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>334</volume>
          <fpage>939</fpage>
          <lpage>945</lpage>
        </citation>
        <citation citation-type="display-unstructured">Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939&#x2013;945 <pub-id pub-id-type="pmid">8596594</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MacKinnon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shurraw</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akbari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Knoll</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Jaffey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data</article-title>
          <source>Am J Kidney Dis</source>
          <year>2006</year>
          <volume>48</volume>
          <fpage>8</fpage>
          <lpage>12</lpage>
        </citation>
        <citation citation-type="display-unstructured">MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8&#x2013;12 <pub-id pub-id-type="pmid">16797382</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horiuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dzau</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II type 2 receptor mediates programmed cell death</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>156</fpage>
          <lpage>160</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yamada T, Horiuchi T, Dzau VJ (1996) Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156&#x2013;160 <pub-id pub-id-type="pmid">8552595</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Steckelings</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bottari</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Metzger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The angiotensin AT<sub>2</sub>-receptor mediates inhibition of cell proliferation in coronary endothelial cells</article-title>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>95</volume>
          <fpage>651</fpage>
          <lpage>657</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stoll M, Steckelings M, Paul M, Bottari SP, Metzger R, Unger T (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651&#x2013;657 <pub-id pub-id-type="pmid">7860748</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steckelings</surname>
              <given-names>UM</given-names>
            </name>
            <name>
              <surname>Kaschina</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The AT2 receptor&#x2014;a matter of love and hate</article-title>
          <source>Peptides</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>1401</fpage>
          <lpage>1409</lpage>
        </citation>
        <citation citation-type="display-unstructured">Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor&#x2013;a matter of love and hate. Peptides 26:1401&#x2013;1409 <pub-id pub-id-type="pmid">16042980</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siragy</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>AT(1) and AT(2) receptors in the kidney: role in disease and treatment</article-title>
          <source>Am J Kidney Dis</source>
          <year>2000</year>
          <volume>36</volume>
          <issue>3 Suppl 1</issue>
          <fpage>S4</fpage>
          <lpage>S9</lpage>
        </citation>
        <citation citation-type="display-unstructured">Siragy HM (2000) AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 36 [3 Suppl 1]:S4&#x2013;9 <pub-id pub-id-type="pmid">10986153</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Inagami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction</article-title>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>53</volume>
          <fpage>937</fpage>
          <lpage>944</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937&#x2013;944 <pub-id pub-id-type="pmid">9551401</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohkubo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nozawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Murasawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kijima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsutumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shibazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iwasaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inada</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism</article-title>
          <source>Circulation</source>
          <year>1997</year>
          <volume>96</volume>
          <fpage>3954</fpage>
          <lpage>3962</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96:3954&#x2013;3962 <pub-id pub-id-type="pmid">9403620</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications</article-title>
          <source>Kidney Int</source>
          <year>2005</year>
          <volume>67</volume>
          <fpage>799</fpage>
          <lpage>812</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799&#x2013;812 <pub-id pub-id-type="pmid">15698420</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ots</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Troy</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rennke</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1998</year>
          <volume>9</volume>
          <fpage>224</fpage>
          <lpage>230</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM (1998) Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224&#x2013;230 <pub-id pub-id-type="pmid">9527398</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>L-J</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aldigier</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Rossini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Marcantoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Regression of glomerulosclerosis with high dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>966</fpage>
          <lpage>976</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma L-J, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB (2005) Regression of glomerulosclerosis with high dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16:966&#x2013;976 <pub-id pub-id-type="pmid">15728787</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Donnert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin type 2 receptor antagonist (AT2RA) worsens glomerulosclerosis in the rat remnant kidney model</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>654A</fpage>
        </citation>
        <citation citation-type="display-unstructured">Naito T, Ma L, Donnert E, Fogo AB (2005) Angiotensin type 2 receptor antagonist (AT2RA) worsens glomerulosclerosis in the rat remnant kidney model. J Am Soc Nephrol 16:654A </citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maeshima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Odawara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kashihara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamasaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Makino</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model</article-title>
          <source>Am J Physiol Renal Physiol</source>
          <year>2004</year>
          <volume>286</volume>
          <fpage>F516</fpage>
          <lpage>F525</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hashimoto N, Maeshima Y, Satoh M, Odawara M, Sugiyama H, Kashihara N, Matsubara H, Yamasaki Y, Makino H (2004) Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286:F516&#x2013;F525 <pub-id pub-id-type="pmid">14583437</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pisani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Balletta</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Nicola</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Savino</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Andreucci</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Minutolo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Additive antiproteinuric effect of converting enzyme inhibtion and losartan in normotensive patients with IgA nephropathy</article-title>
          <source>Am J Kidney Dis</source>
          <year>1999</year>
          <volume>33</volume>
          <fpage>851</fpage>
          <lpage>856</lpage>
        </citation>
        <citation citation-type="display-unstructured">Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R (1999) Additive antiproteinuric effect of converting enzyme inhibtion and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851&#x2013;856 <pub-id pub-id-type="pmid">10213639</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hebert</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Falkenhain</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Nahman</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Cosio</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>O&#x2019;Dorisio</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy</article-title>
          <source>Am J Nephrol</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>1</fpage>
          <lpage>6</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O&#x2019;Dorisio TM (1999) Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 19:1&#x2013;6 <pub-id pub-id-type="pmid">10085442</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mogensen</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Neldam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tikkanen</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Oren</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Viskoper</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Randomised controlled trial of dual blockade of renin&#x2013;angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study</article-title>
          <source>BMJ</source>
          <year>2000</year>
          <volume>321</volume>
          <fpage>1440</fpage>
          <lpage>1444</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin&#x2013;angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440&#x2013;1444 <pub-id pub-id-type="pmid">11110735</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakao</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kayano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ideura</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>117</fpage>
          <lpage>124</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117&#x2013;124 <pub-id pub-id-type="pmid">12531578</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taal</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Combination ACEI and ARB therapy: additional benefit in renoprotection?</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2002</year>
          <volume>11</volume>
          <fpage>377</fpage>
          <lpage>381</lpage>
        </citation>
        <citation citation-type="display-unstructured">Taal MW, Brenner BM (2002) Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 11:377&#x2013;381 <pub-id pub-id-type="pmid">12105385</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishiyama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Seth</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Navar</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats</article-title>
          <source>Hypertension</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>129</fpage>
          <lpage>134</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nishiyama A, Seth DM, Navar LG (2002) Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39:129&#x2013;134 <pub-id pub-id-type="pmid">11799091</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Azizi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nussberger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>NK</given-names>
            </name>
          </person-group>
          <article-title>Renin inhibition with aliskiren: where are we now, and where are we going?</article-title>
          <source>J Hypertens</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>243</fpage>
          <lpage>256</lpage>
        </citation>
        <citation citation-type="display-unstructured">Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243&#x2013;256 <pub-id pub-id-type="pmid">16508564</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orth</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Weinreich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>B&#xF6;nisch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Weih</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells</article-title>
          <source>Exp Nephrol</source>
          <year>1995</year>
          <volume>3</volume>
          <fpage>23</fpage>
          <lpage>33</lpage>
        </citation>
        <citation citation-type="display-unstructured">Orth SR, Weinreich T, B&#xF6;nisch S, Weih M, Ritz E (1995) Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 3:23&#x2013;33 <pub-id pub-id-type="pmid">7712140</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Neilson</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II as a renal growth factor</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1993</year>
          <volume>3</volume>
          <fpage>1531</fpage>
          <lpage>1540</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wolf G, Neilson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531&#x2013;1540 <pub-id pub-id-type="pmid">8507808</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ketteler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Border</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-b and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis?</article-title>
          <source>Annu Rev Physiol</source>
          <year>1995</year>
          <volume>57</volume>
          <fpage>279</fpage>
          <lpage>295</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ketteler M, Noble NA, Border WA (1995) Transforming growth factor-b and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57:279&#x2013;295 <pub-id pub-id-type="pmid">7778869</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: a new mechanism for the anti-fibrotic effect of renin&#x2013;angiotensin inhibition</article-title>
          <source>Kidney Int</source>
          <year>1997</year>
          <volume>51</volume>
          <fpage>164</fpage>
          <lpage>172</lpage>
        </citation>
        <citation citation-type="display-unstructured">Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A (1997) Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: a new mechanism for the anti-fibrotic effect of renin&#x2013;angiotensin inhibition. Kidney Int 51:164&#x2013;172 <pub-id pub-id-type="pmid">8995730</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo</article-title>
          <source>Kidney Int</source>
          <year>2000</year>
          <volume>58</volume>
          <fpage>251</fpage>
          <lpage>259</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB (2000) Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58:251&#x2013;259 <pub-id pub-id-type="pmid">10886570</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>
          <article-title>Aldosterone and end-organ damage</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>235</fpage>
          <lpage>241</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brown NJ (2005) Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14:235&#x2013;241 <pub-id pub-id-type="pmid">15821416</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Epstein</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Aldosterone blockade: an emerging strategy for abrogating progressive renal disease</article-title>
          <source>Am J Med</source>
          <year>2006</year>
          <volume>119</volume>
          <fpage>912</fpage>
          <lpage>919</lpage>
        </citation>
        <citation citation-type="display-unstructured">Epstein M (2006) Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119:912&#x2013;919 <pub-id pub-id-type="pmid">17071154</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weisberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>
          <article-title>Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>1064</fpage>
          <lpage>1072</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69:1064&#x2013;1072 <pub-id pub-id-type="pmid">16528256</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bianchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bigazzi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Campese</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
          <article-title>Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>2116</fpage>
          <lpage>2123</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bianchi S, Bigazzi R, Campese VM (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116&#x2013;2123 <pub-id pub-id-type="pmid">17035949</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinberger</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Luft</surname>
              <given-names>FC</given-names>
            </name>
          </person-group>
          <article-title>Comprehensive suppression of the renin&#x2013;angiotensin&#x2013;aldosterone system in chronic kidney disease: covering all of the bases</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>2051</fpage>
          <lpage>2053</lpage>
        </citation>
        <citation citation-type="display-unstructured">Weinberger MH, Luft FC (2006) Comprehensive suppression of the renin&#x2013;angiotensin&#x2013;aldosterone system in chronic kidney disease: covering all of the bases. Kidney Int 70:2051&#x2013;2053 <pub-id pub-id-type="pmid">17136130</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nyengaard</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy</article-title>
          <source>Kidney Int</source>
          <year>1993</year>
          <volume>43</volume>
          <fpage>1049</fpage>
          <lpage>1057</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nyengaard JR (1993) Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy. Kidney Int 43:1049&#x2013;1057 <pub-id pub-id-type="pmid">8510382</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcussen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nyengaard</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries</article-title>
          <source>Lab Invest</source>
          <year>1994</year>
          <volume>70</volume>
          <fpage>868</fpage>
          <lpage>874</lpage>
        </citation>
        <citation citation-type="display-unstructured">Marcussen N, Nyengaard JR, Christensen S (1994) Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries. Lab Invest 70:868&#x2013;874 <pub-id pub-id-type="pmid">8015291</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nyengaard</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Rasch</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes</article-title>
          <source>Diabetologia</source>
          <year>1993</year>
          <volume>36</volume>
          <fpage>189</fpage>
          <lpage>194</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nyengaard JR, Rasch R (1993) The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36:189&#x2013;194 <pub-id pub-id-type="pmid">8462766</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akaoka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>RHR</given-names>
            </name>
            <name>
              <surname>Raafat</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Glomerular morphometry in childhood reflux nephropathy, emphasizing the capillary changes</article-title>
          <source>Kidney Int</source>
          <year>1995</year>
          <volume>47</volume>
          <fpage>1108</fpage>
          <lpage>1114</lpage>
        </citation>
        <citation citation-type="display-unstructured">Akaoka K, White RHR, Raafat F (1995) Glomerular morphometry in childhood reflux nephropathy, emphasizing the capillary changes. Kidney Int 47:1108&#x2013;1114 <pub-id pub-id-type="pmid">7783408</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adamczak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Krtil</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tyralla</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>2833</fpage>
          <lpage>2842</lpage>
        </citation>
        <citation citation-type="display-unstructured">Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833&#x2013;2842 <pub-id pub-id-type="pmid">14569093</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adamczak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Amann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>3063</fpage>
          <lpage>3072</lpage>
        </citation>
        <citation citation-type="display-unstructured">Adamczak M, Gross ML, Amann K, Ritz E (2004) Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15:3063&#x2013;3072 <pub-id pub-id-type="pmid">15579509</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aldigier</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kanjanabuch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>L-J</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Regression of existing glomerulosclerosis by inhibition of aldosterone</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>3306</fpage>
          <lpage>3314</lpage>
        </citation>
        <citation citation-type="display-unstructured">Aldigier JC, Kanjanabuch T, Ma L-J, Brown NJ, Fogo AB (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16:3306&#x2013;3314 <pub-id pub-id-type="pmid">16192423</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fioretto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Steffes</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Sutherland</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Goetz</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Reversal of lesions of diabetic nephropathy after pancreas transplantation</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>339</volume>
          <fpage>69</fpage>
          <lpage>75</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69&#x2013;75 <pub-id pub-id-type="pmid">9654536</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hotta</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Furuta</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chiba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tomioka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taguma</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Regression of IgA nephropathy: a repeat biopsy study</article-title>
          <source>Am J Kidney Dis</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>493</fpage>
          <lpage>502</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 39:493&#x2013;502 <pub-id pub-id-type="pmid">11877568</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fine</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Hammerman</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Abboud</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Evolving role of growth factors in the renal response to acute and chronic disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1992</year>
          <volume>2</volume>
          <fpage>1163</fpage>
          <lpage>1170</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fine LG, Hammerman MR, Abboud HE (1992) Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol 2:1163&#x2013;1170 <pub-id pub-id-type="pmid">1591357</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kashgarian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sterzel</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>The pathobiology of the mesangium</article-title>
          <source>Kidney Int</source>
          <year>1992</year>
          <volume>41</volume>
          <fpage>524</fpage>
          <lpage>529</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kashgarian M, Sterzel RB (1992) The pathobiology of the mesangium. Kidney Int 41:524&#x2013;529 <pub-id pub-id-type="pmid">1573822</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>1756</fpage>
          <lpage>1764</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yang HC, Ma LJ, Ma J, Fogo AB (2006) Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69:1756&#x2013;1764 <pub-id pub-id-type="pmid">16598202</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmid</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Henger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kretzler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Molecular approaches to chronic kidney disease</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>123</fpage>
          <lpage>129</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schmid H, Henger A, Kretzler M (2006) Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 15:123&#x2013;129 <pub-id pub-id-type="pmid">16481877</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Shyr</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Donnert</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Caprioli</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Proteomic patterns and prediction of glomerulosclerosis and its mechanisms</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>2967</fpage>
          <lpage>2975</lpage>
        </citation>
        <citation citation-type="display-unstructured">Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB (2005) Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16:2967&#x2013;2975 <pub-id pub-id-type="pmid">16079267</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eddy</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>2999</fpage>
          <lpage>3012</lpage>
        </citation>
        <citation citation-type="display-unstructured">Eddy AA, Fogo AB (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17:2999&#x2013;3012 <pub-id pub-id-type="pmid">17035608</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YQ</given-names>
            </name>
            <name>
              <surname>Blevins</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Nadeau</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Meranze</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 expression</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>336</fpage>
          <lpage>344</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE (2000) Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 expression. J Clin Endocrinol Metab 85:336&#x2013;344 <pub-id pub-id-type="pmid">10634408</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gaspert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carlesso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barty</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(&#x2212;/&#x2212;) mice</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>163</volume>
          <fpage>1261</fpage>
          <lpage>1273</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB (2003) Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(&#x2212;/&#x2212;) mice. Am J Pathol 163:1261&#x2013;1273 <pub-id pub-id-type="pmid">14507636</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaedeke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Border</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II, TGF-beta and renal fibrosis</article-title>
          <source>Contrib Nephrol</source>
          <year>2001</year>
          <volume>135</volume>
          <fpage>153</fpage>
          <lpage>160</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gaedeke J, Peters H, Noble NA, Border WA (2001) Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 135:153&#x2013;160 <pub-id pub-id-type="pmid">11705280</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopp</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Factor</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Mozes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nagy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bottinger</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Klotman</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Thorgeirsson</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Transgenic mice with increased levels of TGF-&#x3B2;1 develop progressive renal disease</article-title>
          <source>Lab Invest</source>
          <year>1996</year>
          <volume>74</volume>
          <fpage>991</fpage>
          <lpage>1003</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased levels of TGF-&#x3B2;1 develop progressive renal disease. Lab Invest 74:991&#x2013;1003 <pub-id pub-id-type="pmid">8667617</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Raines</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Floege</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pritzl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alpers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor</article-title>
          <source>J Exp Med</source>
          <year>1992</year>
          <volume>175</volume>
          <fpage>1413</fpage>
          <lpage>1416</lpage>
        </citation>
        <citation citation-type="display-unstructured">Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R (1992) Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175:1413&#x2013;1416 <pub-id pub-id-type="pmid">1569407</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Border</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Languino</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Sporn</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Ruoslahti</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1</article-title>
          <source>Nature</source>
          <year>1990</year>
          <volume>346</volume>
          <fpage>371</fpage>
          <lpage>374</lpage>
        </citation>
        <citation citation-type="display-unstructured">Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371&#x2013;374 <pub-id pub-id-type="pmid">2374609</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christ</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McCartney-Francis</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mizel</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Mackall</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Gress</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Hines</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Karlsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wahl</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Immune dysregulation in TGF-beta 1-deficient mice</article-title>
          <source>J Immunol</source>
          <year>1994</year>
          <volume>153</volume>
          <fpage>1936</fpage>
          <lpage>1946</lpage>
        </citation>
        <citation citation-type="display-unstructured">Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, Wahl SM (1994) Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 153:1936&#x2013;1946 <pub-id pub-id-type="pmid">8051399</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>L-J</given-names>
            </name>
            <name>
              <surname>Sharda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hong Ling</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pozzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ledbetter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Divergent effects of low vs high dose anti-TGF-&#x3B2; antibody in puromycin aminonucleoside nephropathy in rats</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>65</volume>
          <fpage>106</fpage>
          <lpage>115</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma L-J, Sharda J, Hong Ling H, Pozzi A, Ledbetter S, Fogo AB (2004) Divergent effects of low vs high dose anti-TGF-&#x3B2; antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106&#x2013;115 <pub-id pub-id-type="pmid">14675041</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wanna</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gudehithlu</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Garber</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Dunea</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Arruda</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta1 reverses transformation</article-title>
          <source>Transl Res</source>
          <year>2006</year>
          <volume>148</volume>
          <fpage>142</fpage>
          <lpage>148</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sam R, Wanna L, Gudehithlu KP, Garber SL, Dunea G, Arruda JA, Singh AK (2006) Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta1 reverses transformation. Transl Res 148:142&#x2013;148 <pub-id pub-id-type="pmid">16938652</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiffer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bitzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Dijke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mundel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bottinger</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis in podocytes induced by TGF-beta and Smad7</article-title>
          <source>J Clin Invest</source>
          <year>2001</year>
          <volume>108</volume>
          <fpage>807</fpage>
          <lpage>816</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807&#x2013;816 <pub-id pub-id-type="pmid">11560950</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Bitzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ju</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mundel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bottinger</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>3211</fpage>
          <lpage>3221</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP (2005) TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 16:3211&#x2013;3221 <pub-id pub-id-type="pmid">16207831</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Breyer</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease</article-title>
          <source>Kidney Int</source>
          <year>2001</year>
          <volume>60</volume>
          <fpage>14</fpage>
          <lpage>30</lpage>
        </citation>
        <citation citation-type="display-unstructured">Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60:14&#x2013;30 <pub-id pub-id-type="pmid">11422732</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buckingham</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Toseland</surname>
              <given-names>Al-BarazanjiKA</given-names>
            </name>
            <name>
              <surname>Slaughter</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Connor</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Bond</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Clapham</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats</article-title>
          <source>Diabetes</source>
          <year>1998</year>
          <volume>47</volume>
          <fpage>1326</fpage>
          <lpage>1334</lpage>
        </citation>
        <citation citation-type="display-unstructured">Buckingham RE, Al-Barazanji KA Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC (1998) Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326&#x2013;1334 <pub-id pub-id-type="pmid">9703335</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Marcantoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Linton</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Fazio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats</article-title>
          <source>Kidney Int</source>
          <year>2001</year>
          <volume>59</volume>
          <fpage>1899</fpage>
          <lpage>1910</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899&#x2013;1910 <pub-id pub-id-type="pmid">11318962</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shankland</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>The podocyte&#x2019;s response to injury: role in proteinuria and glomerulosclerosis</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>2131</fpage>
          <lpage>2147</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shankland SJ (2006) The podocyte&#x2019;s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69:2131&#x2013;2147 <pub-id pub-id-type="pmid">16688120</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wharram</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Goyal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wiggins</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sanden</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Filipiak</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Saunders</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Dysko</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Holzman</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Wiggins</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>2941</fpage>
          <lpage>2952</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941&#x2013;2952 <pub-id pub-id-type="pmid">16107576</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsusaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Xin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Niwa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akatsuka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hashizume</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>QC</given-names>
            </name>
            <name>
              <surname>Pastan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>1013</fpage>
          <lpage>1023</lpage>
        </citation>
        <citation citation-type="display-unstructured">Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I (2005) Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 16:1013&#x2013;1023 <pub-id pub-id-type="pmid">15758046</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Motojima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsusaka</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>205</fpage>
          <lpage>210</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ichikawa I, Ma J, Motojima M, Matsusaka T (2005) Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 14:205&#x2013;210 <pub-id pub-id-type="pmid">15821411</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Combs</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Shankland</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Setzer</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Hudkins</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Alpers</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
          <article-title>Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney</article-title>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>53</volume>
          <fpage>892</fpage>
          <lpage>896</lpage>
        </citation>
        <citation citation-type="display-unstructured">Combs HL, Shankland SJ, Setzer SV, Hudkins KL, Alpers CE (1998) Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 53:892&#x2013;896 <pub-id pub-id-type="pmid">9551395</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shankland</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Cell cycle regulatory proteins in glomerular disease</article-title>
          <source>Kidney Int</source>
          <year>1999</year>
          <volume>56</volume>
          <fpage>1208</fpage>
          <lpage>1215</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shankland SJ (1999) Cell cycle regulatory proteins in glomerular disease. Kidney Int 56:1208&#x2013;1215 <pub-id pub-id-type="pmid">10610411</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kriz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gretz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lemley</surname>
              <given-names>KV</given-names>
            </name>
          </person-group>
          <article-title>Progression of glomerular diseases: is the podocyte the culprit?</article-title>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>54</volume>
          <fpage>687</fpage>
          <lpage>697</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54:687&#x2013;697 <pub-id pub-id-type="pmid">9734594</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Megyesi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Tamayo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Safirstein</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure</article-title>
          <source>Proc Natl Acad Sci U&#xA0;S&#xA0;A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>10830</fpage>
          <lpage>10835</lpage>
        </citation>
        <citation citation-type="display-unstructured">Megyesi J, Price PM, Tamayo E, Safirstein RL (1999) The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 96:10830&#x2013;10835 <pub-id pub-id-type="pmid">10485911</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eremina</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Quaggin</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>The role of VEGF-A in glomerular development and function</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>9</fpage>
          <lpage>15</lpage>
        </citation>
        <citation citation-type="display-unstructured">Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9&#x2013;15 <pub-id pub-id-type="pmid">15090854</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruotsalainen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ljungberg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wartiovaara</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lenkkeri</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kestila</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jalanko</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tryggvason</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Nephrin is specifically located at the slit diaphragm of glomerular podocytes</article-title>
          <source>Proc Natl Acad Sci U&#xA0;S&#xA0;A.</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>7962</fpage>
          <lpage>7967</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestila M, Jalanko H, Holmberg C, Tryggvason K (1999) Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 96:7962&#x2013;7967 <pub-id pub-id-type="pmid">10393930</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huber</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Benzing</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The slit diaphragm: a signaling platform to regulate podocyte function</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>211</fpage>
          <lpage>216</lpage>
        </citation>
        <citation citation-type="display-unstructured">Huber TB, Benzing T (2005) The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14:211&#x2013;216 <pub-id pub-id-type="pmid">15821412</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shih</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Karpitskii</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dustin</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kanagawa</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Miner</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Congenital nephrotic syndrome in mice lacking CD2-associated protein</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>286</volume>
          <fpage>312</fpage>
          <lpage>315</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312&#x2013;315 <pub-id pub-id-type="pmid">10514378</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaplan</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>North</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Rennke</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>HQ</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Rodriguez-Perez</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Beggs</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Pollak</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>251</fpage>
          <lpage>256</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251&#x2013;256 <pub-id pub-id-type="pmid">10700177</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winn</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Daskalakis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Spurney</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Unexpected role of TRPC6 channel in familial nephrotic syndrome: does it have clinical implications?</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>378</fpage>
          <lpage>387</lpage>
        </citation>
        <citation citation-type="display-unstructured">Winn MP, Daskalakis N, Spurney RF, Middleton JP (2006) Unexpected role of TRPC6 channel in familial nephrotic syndrome: does it have clinical implications? J Am Soc Nephrol 17:378&#x2013;387 <pub-id pub-id-type="pmid">16396961</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boute</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gribouval</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Roselli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Benessy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fuchshuber</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dahan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gubler</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Niaudet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Antignac</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>349</fpage>
          <lpage>354</lpage>
        </citation>
        <citation citation-type="display-unstructured">Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349&#x2013;354 <pub-id pub-id-type="pmid">10742096</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karle</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Uetz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ronner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Glaeser</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fuchshuber</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>388</fpage>
          <lpage>393</lpage>
        </citation>
        <citation citation-type="display-unstructured">Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A (2002) Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:388&#x2013;393 <pub-id pub-id-type="pmid">11805166</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruf</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Lichtenberger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Karle</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Anacleto</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Schultheiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zalewski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Imm</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ruf</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Mucha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bagga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Neuhaus</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fuchshuber</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bakkaloglu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
            <collab>Arbeitsgemeinschaft F&#xFC;r Padiatrische Nephrologie Study Group</collab>
          </person-group>
          <article-title>Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>722</fpage>
          <lpage>732</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F, Arbeitsgemeinschaft F&#xFC;r Padiatrische Nephrologie Study Group (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722&#x2013;732 <pub-id pub-id-type="pmid">14978175</pub-id></citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hinkes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wiggins</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Gbadegesin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vlangos</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Seelow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nurnberg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chaib</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hoskins</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Ashraf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hennies</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Goyal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wharram</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Schachter</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Mudumana</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kerjaschki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Waldherr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ozaltin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bakkaloglu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cleper</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Basel-Vanagaite</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pohl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Griebel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsygin</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Soylu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sorli</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Bunney</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Katan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Attanasio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O&#x2019;toole</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Hasselbacher</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mucha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Airik</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kispert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kelley</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Smrcka</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Gudermann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Holzman</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Nurnberg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible</article-title>
          <source>Nat Genet</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>1397</fpage>
          <lpage>1405</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O&#x2019;toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397&#x2013;1405 <pub-id pub-id-type="pmid">17086182</pub-id></citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mucha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ozaltin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hinkes</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Hasselbacher</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ruf</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Schultheiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hangan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hoskins</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Everding</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Bogdanovic</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Seeman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
            <collab>Members of the APN Study Group</collab>
          </person-group>
          <article-title>Mutations in the Wilms&#x2019; tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9</article-title>
          <source>Pediatr Res</source>
          <year>2006</year>
          <volume>59</volume>
          <fpage>325</fpage>
          <lpage>331</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mucha B, Ozaltin F, Hinkes BG, Hasselbacher K, Ruf RG, Schultheiss M, Hangan D, Hoskins BE, Everding AS, Bogdanovic R, Seeman T, Hoppe B, Hildebrandt F, Members of the APN Study Group (2006) Mutations in the Wilms&#x2019; tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res 59:325&#x2013;331 <pub-id pub-id-type="pmid">16439601</pub-id></citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gbadegesin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hinkes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vlangos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mucha</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hopcian</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome</article-title>
          <source>Pediatr Nephrol</source>
          <year>2007</year>
          <volume>22</volume>
          <fpage>509</fpage>
          <lpage>513</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gbadegesin R, Hinkes B, Vlangos C, Mucha B, Liu J, Hopcian J, Hildebrandt F (2007) Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:509&#x2013;513 <pub-id pub-id-type="pmid">17216259</pub-id></citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawachi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kurihara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yaoita</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Orikasa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shia</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Salant</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states</article-title>
          <source>Kidney Int</source>
          <year>2000</year>
          <volume>57</volume>
          <fpage>1949</fpage>
          <lpage>1961</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kawachi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA, Sakai T, Yamamoto T, Salant DJ, Shimizu F (2000) Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 57:1949&#x2013;1961 <pub-id pub-id-type="pmid">10792613</pub-id></citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forbes</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Candido</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kawachi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Jerums</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Osicka</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria</article-title>
          <source>J Hypertens</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>985</fpage>
          <lpage>992</lpage>
        </citation>
        <citation citation-type="display-unstructured">Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM (2002) Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 20:985&#x2013;992 <pub-id pub-id-type="pmid">12011660</pub-id></citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moller</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Altintas</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Greka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ohse</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Pippin</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Rastaldi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Wawersik</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schiavi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Henger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kretzler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shankland</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Reiser</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Induction of TRPC6 channel in acquired forms of proteinuric kidney disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>29</fpage>
          <lpage>36</lpage>
        </citation>
        <citation citation-type="display-unstructured">Moller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J (2007) Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18:29&#x2013;36 <pub-id pub-id-type="pmid">17167110</pub-id></citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benigni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tomasoni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gagliardini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zoja</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grunkemeyer</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kalluri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2001</year>
          <volume>12</volume>
          <fpage>941</fpage>
          <lpage>948</lpage>
        </citation>
        <citation citation-type="display-unstructured">Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G (2001) Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12:941&#x2013;948 <pub-id pub-id-type="pmid">11316852</pub-id></citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cases</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coll</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Dyslipidemia and the progression of renal disease in chronic renal failure patients</article-title>
          <source>Kidney Int Suppl</source>
          <year>2005</year>
          <volume>99</volume>
          <fpage>S87</fpage>
          <lpage>S93</lpage>
        </citation>
        <citation citation-type="display-unstructured">Cases A, Coll E (2005) Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 99:S87&#x2013;93 <pub-id pub-id-type="pmid">16336584</pub-id></citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keane</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Mulcahy</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Kasiske</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>O&#x2019;Donnell</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Hyperlipidemia and progressive renal disease</article-title>
          <source>Kidney Int</source>
          <year>1991</year>
          <volume>39</volume>
          <issue>Suppl 31</issue>
          <fpage>S41</fpage>
          <lpage>S48</lpage>
        </citation>
        <citation citation-type="display-unstructured">Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O&#x2019;Donnell MP (1991) Hyperlipidemia and progressive renal disease. Kidney Int 39 [Suppl 31]:S41&#x2013;S48 </citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Keane</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in statins and the kidney</article-title>
          <source>Kidney Int Suppl</source>
          <year>1999</year>
          <volume>71</volume>
          <fpage>S2</fpage>
          <lpage>S5</lpage>
        </citation>
        <citation citation-type="display-unstructured">Oda H, Keane WF (1999) Recent advances in statins and the kidney. Kidney Int Suppl 71:S2&#x2013;S5 <pub-id pub-id-type="pmid">10412725</pub-id></citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fried</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Orchard</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Kasiske</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Effect of lipid reduction on the progression of renal disease: a meta-analysis</article-title>
          <source>Kidney Int</source>
          <year>2001</year>
          <volume>59</volume>
          <fpage>260</fpage>
          <lpage>269</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260&#x2013;269 <pub-id pub-id-type="pmid">11135079</pub-id></citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tonelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moye</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sacks</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Curhan</surname>
              <given-names>GC</given-names>
            </name>
            <collab>Cholesterol and Recurrent Events Trial Investigators</collab>
          </person-group>
          <article-title>Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>1605</fpage>
          <lpage>1613</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605&#x2013;1613 <pub-id pub-id-type="pmid">12761262</pub-id></citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bertani</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?</article-title>
          <source>Kidney Int</source>
          <year>1990</year>
          <volume>38</volume>
          <fpage>384</fpage>
          <lpage>394</lpage>
        </citation>
        <citation citation-type="display-unstructured">Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384&#x2013;394 <pub-id pub-id-type="pmid">2232481</pub-id></citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruggenenti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Time to abandon microalbuminuria?</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>1214</fpage>
          <lpage>1222</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ruggenenti P, Remuzzi G (2006) Time to abandon microalbuminuria? Kidney Int 70:1214&#x2013;1222 <pub-id pub-id-type="pmid">16871239</pub-id></citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ziyadeh</surname>
              <given-names>FN</given-names>
            </name>
            <name>
              <surname>Stahl</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>66</volume>
          <fpage>1849</fpage>
          <lpage>1858</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wolf G, Schroeder R, Ziyadeh FN, Stahl RA (2004) Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int 66:1849&#x2013;1858 <pub-id pub-id-type="pmid">15496155</pub-id></citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perico</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Codreanu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schieppati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of disease progression in proteinuric nephropathies</article-title>
          <source>Kidney Int Suppl</source>
          <year>2005</year>
          <volume>94</volume>
          <fpage>S79</fpage>
          <lpage>S82</lpage>
        </citation>
        <citation citation-type="display-unstructured">Perico N, Codreanu I, Schieppati A, Remuzzi G (2005) Pathophysiology of disease progression in proteinuric nephropathies. Kidney Int Suppl 94:S79&#x2013;S82 <pub-id pub-id-type="pmid">15752247</pub-id></citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbate</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zoja</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>How does proteinuria cause progressive renal damage?</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>2974</fpage>
          <lpage>2984</lpage>
        </citation>
        <citation citation-type="display-unstructured">Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17:2974&#x2013;2984 <pub-id pub-id-type="pmid">17035611</pub-id></citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Kanellis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hugo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kerjaschki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Role of the microvascular endothelium in progressive renal disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>806</fpage>
          <lpage>816</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ (2002) Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806&#x2013;816 <pub-id pub-id-type="pmid">11856789</pub-id></citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kipari</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Macrophage-mediated renal cell death</article-title>
          <source>Kidney Int</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>760</fpage>
          <lpage>761</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kipari T, Hughes J (2002) Macrophage-mediated renal cell death. Kidney Int 61:760&#x2013;761 <pub-id pub-id-type="pmid">11849421</pub-id></citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishidoya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morrissey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McCracken</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Reyes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Klahr</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction</article-title>
          <source>Kidney Int</source>
          <year>1995</year>
          <volume>47</volume>
          <fpage>1285</fpage>
          <lpage>1294</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285&#x2013;1294 <pub-id pub-id-type="pmid">7637258</pub-id></citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujinaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsusaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Linton</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Fazio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Homma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2002</year>
          <volume>110</volume>
          <fpage>1859</fpage>
          <lpage>1868</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I (2002) Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110:1859&#x2013;1868 <pub-id pub-id-type="pmid">12488436</pub-id></citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caramori</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sisson-Ross</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Groppoli</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Basgen</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mauer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients</article-title>
          <source>Kidney Int</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>2058</fpage>
          <lpage>2066</lpage>
        </citation>
        <citation citation-type="display-unstructured">Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M (2002) An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 61:2058&#x2013;2066 <pub-id pub-id-type="pmid">12028446</pub-id></citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Awqati</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Stem cells in the kidney</article-title>
          <source>Kidney Int</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>387</fpage>
          <lpage>395</lpage>
        </citation>
        <citation citation-type="display-unstructured">Al-Awqati Q, Oliver JA (2002) Stem cells in the kidney. Kidney Int 61:387&#x2013;395 <pub-id pub-id-type="pmid">11849378</pub-id></citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neilson</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of disease: fibroblasts&#x2014;a new look at an old problem</article-title>
          <source>Nat Clin Pract Nephrol</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>101</fpage>
          <lpage>108</lpage>
        </citation>
        <citation citation-type="display-unstructured">Neilson EG (2006) Mechanisms of disease: fibroblasts&#x2014;a new look at an old problem. Nat Clin Pract Nephrol 2:101&#x2013;108 <pub-id pub-id-type="pmid">16932401</pub-id></citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Hypertensive risk factors in kidney disease in African Americans</article-title>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>63</volume>
          <issue>Suppl 83</issue>
          <fpage>S17</fpage>
          <lpage>S21</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fogo AB (2003) Hypertensive risk factors in kidney disease in African Americans. Kidney Int 63 Suppl 83:S17&#x2013;S21 </citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andreoli</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children</article-title>
          <source>Adv Ren Replace Ther</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>105</fpage>
          <lpage>109</lpage>
        </citation>
        <citation citation-type="display-unstructured">Andreoli SP (2004) Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children. Adv Ren Replace Ther 11:105&#x2013;109 <pub-id pub-id-type="pmid">14730545</pub-id></citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barker</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Osmond</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales</article-title>
          <source>Lancet</source>
          <year>1986</year>
          <volume>1</volume>
          <fpage>1077</fpage>
          <lpage>1081</lpage>
        </citation>
        <citation citation-type="display-unstructured">Barker DJ, Osmond C (1986) Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet 1:1077&#x2013;1081 <pub-id pub-id-type="pmid">2871345</pub-id></citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brenner</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Glomeruli and blood pressure. Less of one, more the other?</article-title>
          <source>Am J Hypertens</source>
          <year>1988</year>
          <volume>1</volume>
          <fpage>335</fpage>
          <lpage>347</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brenner BM, Garcia DL, Anderson S (1988) Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335&#x2013;347 <pub-id pub-id-type="pmid">3063284</pub-id></citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleinman</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kessel</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Racial differences in low birth weight. Trends and risk factors</article-title>
          <source>N Engl J Med</source>
          <year>1987</year>
          <volume>317</volume>
          <fpage>749</fpage>
          <lpage>753</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kleinman JC, Kessel SS (1987) Racial differences in low birth weight. Trends and risk factors. N Engl J Med 317:749&#x2013;753 <pub-id pub-id-type="pmid">3627185</pub-id></citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pesce</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okoye</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Striker</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Striker</surname>
              <given-names>GE</given-names>
            </name>
          </person-group>
          <article-title>Glomerular size and the incidence of renal disease in African Americans and Caucasians</article-title>
          <source>J Nephrol</source>
          <year>1994</year>
          <volume>7</volume>
          <fpage>355</fpage>
          <lpage>358</lpage>
        </citation>
        <citation citation-type="display-unstructured">Pesce C, Schmidt K, Fogo A, Okoye MI, Kim R, Striker LJ, Striker GE (1994) Glomerular size and the incidence of renal disease in African Americans and Caucasians. J Nephrol 7:355&#x2013;358 </citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoy</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Hughson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Douglas-Denton</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bertram</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>104</fpage>
          <lpage>110</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hoy WE, Hughson MD, Singh GR, Douglas-Denton R, Bertram JF (2006) Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int 70:104&#x2013;110 <pub-id pub-id-type="pmid">16723986</pub-id></citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Douglas-Denton</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>McNamara</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Hoy</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Hughson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Bertram</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Does nephron number matter in the development of kidney disease?</article-title>
          <source>Ethn Dis</source>
          <year>2006</year>
          <volume>16</volume>
          <issue>2 Suppl 2</issue>
          <fpage>S240</fpage>
          <lpage>S245</lpage>
        </citation>
        <citation citation-type="display-unstructured">Douglas-Denton RN, McNamara BJ, Hoy WE, Hughson MD, Bertram JF (2006) Does nephron number matter in the development of kidney disease? Ethn Dis 16 [2 Suppl 2]:S240&#x2013;S245 </citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Austin</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Boumpas</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Vaughan</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Balow</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>1995</year>
          <volume>10</volume>
          <fpage>1620</fpage>
          <lpage>1628</lpage>
        </citation>
        <citation citation-type="display-unstructured">Austin HA, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620&#x2013;1628 <pub-id pub-id-type="pmid">8559480</pub-id></citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casanova</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mazzucco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barbiano di Belgiojoso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Motta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boldorini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Genderini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Monga</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study</article-title>
          <source>Am J Kidney Dis</source>
          <year>1995</year>
          <volume>26</volume>
          <fpage>446</fpage>
          <lpage>453</lpage>
        </citation>
        <citation citation-type="display-unstructured">Casanova S, Mazzucco G, Barbiano di Belgiojoso G, Motta M, Boldorini R, Genderini A, Monga G (1995) Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 26:446&#x2013;453 <pub-id pub-id-type="pmid">7645552</pub-id></citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Tay</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events</article-title>
          <source>Kidney Int</source>
          <year>2000</year>
          <volume>58</volume>
          <fpage>1797</fpage>
          <lpage>1804</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wang Y, Wang YP, Tay YC, Harris DC (2000) Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 58:1797&#x2013;1804 <pub-id pub-id-type="pmid">11012915</pub-id></citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Model of robust induction of glomerulosclerosis in mice: importance of genetic background</article-title>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>64</volume>
          <fpage>350</fpage>
          <lpage>355</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ma LJ, Fogo AB (2003) Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 64:350&#x2013;355 <pub-id pub-id-type="pmid">12787428</pub-id></citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Breyer</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Characterization of susceptibility of inbred mouse strains to diabetic nephropathy</article-title>
          <source>Diabetes</source>
          <year>2005</year>
          <volume>54</volume>
          <fpage>2628</fpage>
          <lpage>2637</lpage>
        </citation>
        <citation citation-type="display-unstructured">Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628&#x2013;2637 <pub-id pub-id-type="pmid">16123351</pub-id></citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kuriyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Atsumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tomonari</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mitarai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamaguchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawaguchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Matsuoka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin-I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus: risk for progression to chronic renal failure and mortality</article-title>
          <source>Kidney Int</source>
          <year>1996</year>
          <volume>50</volume>
          <fpage>657</fpage>
          <lpage>664</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O (1996) Angiotensin-I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus: risk for progression to chronic renal failure and mortality. Kidney Int 50:657&#x2013;664 <pub-id pub-id-type="pmid">8840299</pub-id></citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jeunemaitre</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gallois</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rodier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chatellier</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dusselier</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kahal</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chaillous</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Halimi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sackmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bauduceau</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bled</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Passa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alhenc-Gelas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Contribution of genetic polymorphism in the renin&#x2013;angiotensin system to the development of renal complications in insulin-dependent diabetes</article-title>
          <source>J Clin Invest</source>
          <year>1997</year>
          <volume>99</volume>
          <fpage>1585</fpage>
          <lpage>1595</lpage>
        </citation>
        <citation citation-type="display-unstructured">Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F (1997) Contribution of genetic polymorphism in the renin&#x2013;angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99:1585&#x2013;1595 <pub-id pub-id-type="pmid">9120002</pub-id></citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brock</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Hunley</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Role of the renin&#x2013;angiotensin system in disorders of the urinary tract</article-title>
          <source>J Urol</source>
          <year>1998</year>
          <volume>160</volume>
          <fpage>1812</fpage>
          <lpage>1819</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brock JW 3rd, Hunley TE, Adams MC, Kon V (1998) Role of the renin&#x2013;angiotensin system in disorders of the urinary tract. J Urol 160:1812&#x2013;819 <pub-id pub-id-type="pmid">9783965</pub-id></citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cambien</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Poirier</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lecerf</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cambou</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Arveiler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Luc</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bard</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bara</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ricard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tiret</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Amoyel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alhenc-Gelas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Soubrier</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction</article-title>
          <source>Nature</source>
          <year>1992</year>
          <volume>359</volume>
          <fpage>641</fpage>
          <lpage>644</lpage>
        </citation>
        <citation citation-type="display-unstructured">Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amoyel P, Alhenc-Gelas F, Soubrier F (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641&#x2013;644 <pub-id pub-id-type="pmid">1328889</pub-id></citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Polymorphisms of the renin&#x2013;angiotensin system genes in progressive renal diseases</article-title>
          <source>Kidney Int</source>
          <year>1996</year>
          <volume>50</volume>
          <fpage>732</fpage>
          <lpage>744</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yoshida H, Kon V, Ichikawa I (1996) Polymorphisms of the renin&#x2013;angiotensin system genes in progressive renal diseases. Kidney Int 50:732&#x2013;744 <pub-id pub-id-type="pmid">8872946</pub-id></citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boonstra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Zeeuw</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jong</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Navis</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Role of genetic variability in the renin&#x2013;angiotensin system in diabetic and nondiabetic renal disease</article-title>
          <source>Semin Nephrol</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>580</fpage>
          <lpage>592</lpage>
        </citation>
        <citation citation-type="display-unstructured">Boonstra A, de Zeeuw D, de Jong PE, Navis G (2001) Role of genetic variability in the renin&#x2013;angiotensin system in diabetic and nondiabetic renal disease. Semin Nephrol 21:580&#x2013;592 <pub-id pub-id-type="pmid">11709806</pub-id></citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunley</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Julian</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Summar</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Fogo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kon</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy</article-title>
          <source>Kidney Int</source>
          <year>1996</year>
          <volume>49</volume>
          <fpage>571</fpage>
          <lpage>577</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hunley TE, Julian BA, Phillips JA 3rd, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V (1996) Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49:571&#x2013;577 <pub-id pub-id-type="pmid">8821846</pub-id></citation>
      </ref>
      <ref id="CR135">
        <label>135.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>August</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leventhal</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Suthanthiran</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence</article-title>
          <source>Curr Hypertens Rep</source>
          <year>2000</year>
          <volume>2</volume>
          <fpage>184</fpage>
          <lpage>191</lpage>
        </citation>
        <citation citation-type="display-unstructured">August P, Leventhal B, Suthanthiran M (2000) Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. Curr Hypertens Rep 2:184&#x2013;191 <pub-id pub-id-type="pmid">10981147</pub-id></citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>ANSWERS:</p>
        <p>1. (c) is the correct answer. Podocin mutation occurs in only up to approximately 25% of steroid-resistant NS patients. Minimal-change disease is less likely, as he is steroid resistant and African American. Diffuse mesangial sclerosis is very rare beyond early childhood. Although collapsing glomerulopathy is more frequent in African American than in Caucasian adults, this form of FSGS is more rare than usual-type FSGS, especially in children.</p>
        <p>2. (c) is the correct answer. ACEI is referred as initial treatment for proteinuric patients at risk for CKD, even if they have normal blood pressure. If proteinuria does not respond to ACEI alone, added treatment with ARB may be considered, to decrease proteinuria and, likely, to decrease the decline in GFR. Although diuretic treatment may be warranted for edema, it does not have specific effects to decrease risk of CKD. Spironolactone may provide additional benefit based on early results in proteinuric CKD patients, in addition to ACEI and ARB. Beta blocker is not indicated in this patient without hypertension.</p>
        <p>3. (d) is the correct answer. In this normotensive patient, the effect of therapy on proteinuria is the best indicator of therapeutic efficacy. If the patient develops hypertension, then normalization of blood pressure would be an additional important target for therapy. Edema is also a parameter for evaluation of need for diuretic treatment but not of direct importance for progression of CKD. The drugs listed do not have specific effects on WBC count.</p>
        <p>4. (e) is the correct answer. In this patient with sclerosing lesions, podocyte loss may contribute to progressive damage. Proteinuria is also likely a contributor to interstitial fibrosis, which may be contributed to by infiltrating macrophages. Her blood pressure is elevated, and she likely also has intraglomerular hypertension.</p>
        <p>5. (e) is the correct answer. In this patient, the likely underlying diagnosis is minimal-change disease, in that he has steroid-dependent nephrotic syndrome and still has normal serum creatinine after 6&#xA0;years of relapsing disease. Podocyte loss is not a feature of minimal-change disease. Proteinuria could be a contributor to interstitial fibrosis, more likely if he does not just have selective proteinuria. Dyslipidemia may contribute to renal as well as cardiovascular injury. His blood pressure is normal, as is his serum creatinine, and therefore he likely has normal intraglomerular pressure.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>